Actively Recruiting
Evaluating Non-Operative Management Versus Surgery After Immunotherapy for Early-Stage Mismatch Repair-Deficient Gastrointestinal Cancers
Led by University Hospital, Basel, Switzerland · Updated on 2026-09-18
234
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with non-metastatic, mismatch repair-deficient MMRd or microsatellite instability-high MSI-H gastrointestinal cancers, including colorectal cancer, to evaluate management strategies after immunotherapy. The study has two parts Part A is an observational registry of patients treated with surgery andor immunotherapy, while Part B is a phase II surveillance study for patients showing complete or near-complete response to immune checkpoint inhibitors ICI who wish to avoid surgery. This research aims to understand the safety and outcomes of non-operative management in these patients. Eligible patients receive immune checkpoint inhibitor therapy, such as PD-L1 monotherapy or combination therapy, for up to 6 months or longer if near-complete response occurs. Patients not achieving complete response or unwilling for non-operative management proceed to standard surgery and follow routine follow-up Part A. Those with complete or near-complete response enter an active surveillance program Part B involving clinical assessments, imaging CT or MRI, endoscopy, and optional circulating tumor DNA testing after immunotherapy. Participants undergo regular evaluations including imaging and endoscopy during surveillance to monitor for cancer relapse. The primary outcome is 2-year relapse-free survival in the surveillance group. Patients in the registry are followed according to institutional standards. The study spans several years, with long-term monitoring to assess relapse and response. This approach aims to improve quality of life by potentially avoiding surgery when safely possible.
CONDITIONS
Brief Title
Research on Effective Strategies After Immunotherapy for Mismatch Repair-deficient Early-stage GI Tumors
Research Team
D
Dieter Köberle, Prof. Dr. med.
M
Marco von Strauss und Torney, PD Dr. med.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here